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Individualizedmedical decisionmaking is often complex due to patient treatment response heterogeneity.
Pharmacotherapymay exhibit distinct efficacy and safety profiles for different patient populations. An “opti-
mal” treatment that maximizes clinical benefit for a patient may also lead to concern of safety due to a high
risk of adverse events. Thus, to guide individualized clinical decision making and deliver optimal tailored
treatments, maximizing clinical benefit should be considered in the context of controlling for potential risk.
In this work, we propose two approaches to identify personalized optimal treatment strategy that maxi-
mizes clinical benefit under a constraint on the average risk. We derive the theoretical optimal treatment
rule under the risk constraint and draw an analogy to the Neyman–Pearson lemma to prove the theorem.
We present algorithms that can be easily implemented by any off-the-shelf quadratic programming pack-
age.We conduct extensive simulation studies to show satisfactory risk control whenmaximizing the clinical
benefit. Finally, we apply our method to a randomized trial of type 2 diabetes patients to guide optimal uti-
lization of the first line insulin treatments based on individual patient characteristics while controlling for
the rate of hypoglycemia events. We identify baseline glycated hemoglobin level, body mass index, and
fasting blood glucose as three key factors among 18 biomarkers to differentiate treatment assignments,
and demonstrate a successful control of the risk of hypoglycemia in both the training and testing dataset.
1. Introduction
Treatment of chronic diseases such as diabetes mellitus is often
multifaceted.Whilemaximizing clinical benefit or efficacy is the
primary goal, complications and risks related to safety need to
be taken into account. For example, the goal of treating patients
with type 2 diabetes mellitus is to achieve a glycated hemoglobin
(A1C) level of less than or equal to 7%, the level recommended
by the American Diabetes Association and the European Asso-
ciation for the Study of Diabetes (Inzucchi et al. 2012). To attain
this goal of fast and flexible control of blood glucose levels, oral
hypoglycemic agents or insulin therapies are usually adminis-
tered by clinicians. However, hypoglycemic events are common
adverse events that may have a significant negative impact on
patients. It is associated with adverse short-term and long-term
outcomes, such as increased mortality, seizures, and coma. In
addition, fear of hypoglycemia can lead to medication noncom-
pliance and failure to achieve glycemic control (Cryer, Davis,
and Shamoon 2003). While the progressive nature of the dis-
ease requires an escalating sequence of medications or dose of
insulin, the risk of hypoglycemia and other adverse events may
increase with the intensified treatment (Cryer 2002). Hence,
when choosing an optimal treatment regimen for a patient,
it is necessary to consider both maximizing clinical benefit
(glycemic control) and minimizing risk (hypoglycemia) at the
same time.
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Due to patient’s differential response to a treatment, charac-
terization of individual response heterogeneity has been a criti-
cal component of clinical decision making. Recent literature on
personalized medicine has flourished with methods on using
clinical and biological markers to guide the development of tai-
lored therapies (Su et al. 2009; Lipkovich et al. 2011; Cai et al.
2011; Foster, Taylor, and Ruberg 2011; Zhao et al. 2012). Several
work focuses on identifying a target subgroup of subjects who
are expected to gain substantial benefit from a given treatment,
that is, the right subpopulation for a given treatment (e.g., Fos-
ter, Taylor, and Ruberg 2011). Some recent development aims
for identifying the optimal treatment for a given subject (Qian
and Murphy 2011; Zhao et al. 2012). In particular, to estimate
the optimal treatment for a patient, machine learning methods
such as outcome weighted learning (Zhao et al. 2012; Liu et al.
2014) and alternatives building on double robust estimation in
a semiparametric modeling framework (Zhang et al. 2012) are
proposed.
The above referenced work on estimating optimal treatment
strategy targets one side of clinical decisionmaking—the clinical
benefit and efficacy, but they ignore the potential safety and risk
due to the “optimal” and potentially aggressive treatments. The
important issue of controlling risk while maximizing benefit has
long been recognized in the clinical community where safety
concerns for medications often arise, since the most efficacious
medication for a patient or a subpopulation may also lead to a
higher risk. For example, the recent controversy regarding the
safety of thiazolidinediones for treating diabetes led the new
guidance issued by the Food and Drug Administration on the
need to evaluate the cardiovascular risk of diabetes medica-
tions (http://www.fda.gov/downloads/Drugs/GuidanceCompli
anceRegulatoryInformation/Guidances/ucm071627.pdf). This
new guideline calls for attention to adverse events tomake accu-
rate conclusions about the efficacy and safety of the medication.
In addition, for chronic diseases such as diabetes, the long dura-
tion of treatment may expose patients to higher risk of adverse
events such as hypoglycemia (Cryer, Davis, and Shamoon 2003).
Similar to the phenomenon of the heterogenous treatment
effect measured by the efficacy outcome, patients may exhibit
heterogeneity in their risk profiles depending on the subject-
specific characteristics. For example, Sinclair, Dunning, and
Rodriguez-Mañas (2015) reported that the risk of hypoglycemic
events is higher among elder individuals. As another example, it
is well-known that the relative abundance of drug-metabolizing
enzymes such as cytochrome P450 (CYP450) varies from per-
son to person, and genetic polymorphisms associated with
CYP450 have been identified (Belle and Singh 2008). Therefore,
patients’ adverse reactions to the same drug dosage can show
between-subject heterogeneity. In addition, the efficacy outcome
and safety or toxicity outcome for an individual is correlated.
Increasing a subject’s dosage of amedication leads to an increase
in the efficacy, but may at the same time increase the risk of
adverse events. Thus, in the context of identifying optimal indi-
vidualized treatment rules, the goal of maximizing efficacy out-
come (reward function) needs to be considered in conjunction
with controlling for the risk.
An existing body of literature has considered both efficacy
and safety outcomes for personalized medicine through joint
modeling of the two outcomes (Thall, Nguyen, and Estey 2008;
Houede et al. 2010; Thall 2012; Lee et al. 2015). These Bayesian
approaches construct a utility function or posterior criterion
based on bivariate models of the efficacy and safety outcomes,
and estimate an optimal dosing strategy to maximize the util-
ity function or criterion. Subject-specific covariates are intro-
duced to the bivariate model to estimate personalized opti-
mal dosing strategy. Other authors propose to handle multi-
ple outcomes while maximizing clinical benefit through a con-
ditional regression as in Q-learning. See, for example, Lizotte,
Bowling, and Murphy (2012), Laber, Lizotte, and Ferguson
(2014), and Kosorok and Moodie (2015, chap. 15). Solutions
were obtained by grid search or iterative methods, and no gen-
eral theorem was given for a unified optimal solution. Another
related work (Kosorok and Moodie 2015, chap. 14) proposed
outcomeweighted learningwith a rejection option to reserve the
selection of treatment and leave the actual assignment open to
other considerations (including risk outcomes). Luedtke et al.
(2016) considered to restrict treatment options instead of a risk
outcome.
In contrast to the above existing approaches, here we aim to
estimate the optimal personalized treatment rule to maximize
the clinical benefit while directly impose a constraint such that
the average risk under the optimal treatment assignment is lower
than a predetermined, and clinically meaningful threshold. Our
approach does not require joint modeling of the efficacy and
safety outcome. In addition, by directly controlling the riskwhile
maximizing the efficacy, there is no need to examine the trade-
off between the benefit and risk to form a composite outcome or
utility function, as done in the benefit-risk analysis (Guo et al.
2010) or as required in some existing work (e.g., Houede et al.
2010). How toweight benefit and risk in amanner that addresses
the complexity of the clinical contexts in which a medical deci-
sion is made is a separate issue that deserves attention in its own
right (Moore et al. 2008). In our approach, the problem of how
to compare dissimilar outcomes is avoided.
We translate the scientific goal of maximizing efficacy while
controlling for the risk to a constrained optimization problem,
where the resulting optimal rule is expected to maximize the
clinical reward function and satisfy the risk constraint. We pro-
pose two approaches to solve the risk-constrained learning: one
based on regression model with an additional constraint placed
to bound the average risk (model-based benefit-risk learning,
BR-M), and the other based on outcome weighted learning
(benefit-risk O-learning, BR-O). For the latter, the zero-one loss
in the risk constraint is approximated by a shifted ramp loss
(Huang, Shi, and Suykens 2014) instead of the usual hinge loss to
allow more precise control of the risk bound. The difference of
convex functions algorithm (DC algorithm, Tao and An 1998)
is applied to solve the optimization problem. We derive the the-
oretical optimal treatment rule under the risk constraint and
show a natural connection with finding the optimal rejection
region while controlling for the Type I error rate as given by the
familiar Neyman–Pearson lemma. We perform extensive simu-
lation studies to examine the performance and stability of both
algorithms and compare with utility function-based methods.
Finally, we apply our approach to the realworldmotivating study
to develop personalized treatment rules to guide the administra-
tion of the first line insulin treatment based on individual patient
characteristics while restricting the rate of hypoglycemia events.
2. DURABLE Study: A Type 2 Diabetes Randomized
Clinical Trial
Type 2 diabetes mellitus (T2DM) is a progressive disease, and
the current treatment strategy is one of gradual regimen inten-
sification. When lifestyle intervention and oral anti-diabetic
agents fail to achieve adequate glycemic control, insulin treat-
ments are often appropriate next steps. There are a variety
of insulin initiation options, such as adding basal insulin or
starting with twice-daily premixed insulin. To compare the
efficacy, safety, and durability of two common starter insulin
regimens, a randomized control clinical trial, DURABLE, was
conducted to compare once-daily basal insulin glargine versus
twice-daily insulin lispro mix 75/25 (Fahrbach et al. 2008). This
study enrolled 2091 patients from 242 centers in 11 countries
(Argentina, Australia, Brazil, Canada, Greece, Hungary, India,
theNetherlands, Romania, Spain, and theU.S.) betweenDecem-
ber 2005 and July 2007. The trial was designed with a 6-month
initiation phase to compare safety and efficacy, and a subsequent
24-month maintenance phase to compare durability. The last
patient visit of this trial occurred inDecember 2009. Because the
patients had to be reconsented for the maintenance phase, the
second phase was not a randomized trial any more. Therefore,
we focus on the data from the first 6-month initiation phase,
which consisted of 965 patients on lispro mix and 980 patients
on insulin glargine.
While reducing A1C is an important efficacy goal, con-
trolling hypoglycemia is also particularly crucial for optimiz-
ing insulin treatment regimen and patient care management.
Over-medication with insulin, delays in mealtimes, or insuffi-
cient carbohydrate intake to match insulin dose are some com-
mon causes of hypoglycemia. The Diabetes Complications and
Controls Trial (DCCT) found that intensive therapy for type 1
diabetes patients caused a three-fold increase in hypoglycemic
event rates compared with less aggressive treatment strategy
(UK Prospective Diabetes Study (UKPDS) Group 1998). Simi-
larly, tight glycemic control in type 2 diabetes led to a significant
increase in the incidence of hypoglycemia in theUKProspective
Diabetes Study (UKPDS) (Kosorok and Moodie 2015). Hypo-
glycemia is a major limiting factor in the management of type 1
and type 2 diabetes. Patients having hypoglycemic events have
symptoms ranging from hunger, sweating, to severe cases such
as seizure, coma, and even death. Hypoglycemia management
also relates to significant health care utilization. The mean costs
for hypoglycemia visits were $17,564 for an inpatient admission,
$1387 for an emergency room visit, and $394 for an outpatient
visit (Quilliam et al. 2011). As pointed out by Fidler, Elmelund
Christensen, and Gillard (2011), if we can successfully avoid the
hypoglycemic events, glycemia targets would be much easier to
achieve. Therefore, it is important to have a treatment algorithm
to maximize patients benefit from insulin treatment while con-
trolling for the risk of hypoglycemia.
Our primary efficacy measure (benefit outcome) was A1C at
the study endpoint, and the safety measure (risk outcome) was
daily hypoglycemic event rate. The study enrolled patients with
baseline A1C> 7% with a median of 8.8%. The duration of dia-
betes at baseline ranged from 0.3 to 39 years with a median of
8 years. Our preliminary data analysis indicated that patients’
responses to the treatments were heterogenous. For example, for
patients with baseline A1C > 8.8% versus ≤ 8.8%, their A1C
reductions were 2.44 versus 1.08 (p-value < 0.01), and daily
hypoglycemic rates were 0.061 versus 0.078 (p-value < 0.01);
and for patients with baseline duration of diabetes > 8 years
versus ≤ 8 years, their A1C reductions were 1.752 versus 1.746
(p-value = 0.82), and daily hypoglycemia rates were 0.082 ver-
sus 0.058 (p-value< 0.01). These pooled analyses show that the
efficacy and safety endpoints are associated with some covari-
ates but whether these covariates could further interact with the
treatment assignment is largely unknown. Hence, it is impor-
tant to understand the underlying heterogeneity of treatment
responses for both benefit and risk outcomes so as to derive
the optimal personalized treatment rules to maximize the A1c
reduction while controlling for the risk of hypoglycemia.
3. Personalized Treatment Rules Maximizing Benefit
While Controlling for Risk
3.1. Statistical Framework
LetY denote the benefit outcome andR denote the risk outcome.
Thus, a large Y and small R is desirable. Consider a dichoto-
mous treatment option denoted by A ∈ {−1, 1}. Let X denote
subject-specific feature variables. A treatment rule is then a map
from X to the treatment option domain. For any given treat-
ment rule, say D, the expected benefit and risk are ED[Y ] and
ED[R], respectively, where ED[·] is the expectation under prob-
ability measure PD for (Y,R,A,X ) given that A = D(X ). Our
goal is to estimate a personalized treatment rule that maximizes
the expected benefit while controlling the overall expected risk
to be below a given threshold.
Specifically, we aim to find an optimal treatment rule,
denoted byD∗, such thatD∗ solves{
maxD ED(Y ),
subject to ED(R) ≤ τ, (3.1)
where τ is a prespecified value denoting the maximal tolerance
of the overall risk. For example, in the DURABLE study, Y was
the reduction in HbA1C at the endpoint, Rwas the rate of hypo-
glycemic events, and τ was chosen to be 0.065 hypoglycemic
event/day (or approximately 2 hypoglycemic events/month).
Consider data collected from a randomized trial such as
DURABLE, so (Y,R,A,X ) follows a nondegenerate distribu-
tion P . Furthermore, we assume that the randomization prob-
ability P(A = a|X ) is bounded strictly away from zero for a ∈














dP dP = E
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and the expected risk under the same rule is given as
ED(R) = E
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maximizing the benefit function is equivalent to minimiz-
ing E{I(A = D(X ))Y/p(A|X )}. Treatment rule D(X ) is usu-
ally given as the sign of a decision function, that is, D(X ) =
sign( f (X )), for some function f (X ). Therefore, estimating D∗
using randomized trial data is equivalent to solving⎧⎨⎩ min f E
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As a note, ED[Y ] is termed the value function associated with
the rule D. Some existing work (e.g., Zhao et al. 2012) aims to
maximize this value function to find the optimal treatment rule
but impose no risk control, that is, setting τ = ∞. Here f is
identifiable up to a scale. To estimate the optimal rule, only the
sign of f is required. To ensure identifiability of f , a constraint
on the norm of f (e.g., ‖ f ‖ = 1) can be imposed.
3.2. Theoretical Optimal Treatment Rule
In this section, we will derive an explicit solution for D∗ that
solves (3.2). First, we let δY (X ) = E[Y |X,A = 1] − E[Y |X,A =
−1] and δR(X ) = E[R|X,A = 1] − E[R|X,A = −1]. Note that





δY (X )I( f (X ) > 0)
}
subject to E{δR(X )I( f (X ) > 0)}
≤ α,
where α = τ − E{E(R|A = −1,X )}. Clearly, from the con-
straint, we require that α ≥ E{δR(X )I(δR(X ) < 0)} since oth-
erwise, no f exists. In other words, τ cannot be too small so
that no treatment rule can induce risk below τ . Additionally, we
assume X to be continuous.
To derive the optimal treatment rule, we consider two dif-
ferent domains of X : M = {X : δY (X )δR(X ) ≤ 0} and Mc.
Clearly, for X ∈ M, treatment options yielding higher bene-
fit also reduce risk or treatments yielding lower benefit also
increase risk; while it is the opposite forX ∈ Mc. Hence, forX ∈
M, we choose f ∗(X ) = sign(δY (X )), which gives the largest
benefit and smallest risk.
It only remains to determine f ∗(X ) for X ∈ Mc. The objec-
tive function to be maximized becomes
E{δY (X )I( f (X ) > 0)|X ∈ Mc},
subject to E{δR(X )I( f (X ) > 0)|X ∈ Mc} ≤ α∗,
where
α∗ = α − E{δR(X )I(δY (X ) > 0,X ∈ M)}
P(X ∈ Mc)
= α − E{δR(X )I(δY (X ) > 0, δR(X ) ≤ 0)}
1−P(δY (X )>0, δR(X )≤0)−P(δY (X )≤0, δR(X )>0) .
The optimal rule is given in the following theorem.
Theorem 1. The optimal treatment rule is D∗(X ) =
sign( f ∗(X )), where
D∗(X ) = sign (δY (X )− λ∗δR(X )) ,
where λ∗ = 0 if E[δ+R (X )|X ∈ Mc] ≤ α∗; otherwise, λ∗ solves
equation
E[δR(X )I{δR(X ) > 0, δY (X )/δR(X ) > λ}|X ∈ Mc]
+E[δR(X )I{δR(X )<0, δY (X )/δR(X )<λ}|X∈Mc] = α∗.
The proof of Theorem 1 is given in Appendix A.
Remark 1. The proof of Theorem 1 shows that estimating the
optimal treatment rule is analogous to finding the optimal rejec-
tion region at a givenType I error rate as in theNeyman–Pearson
lemma, which aims to maximize the power under an alterna-
tive hypothesis while controlling the Type I error under the null.
Therefore, if X is not continuous, there may not exist an exact
solution λ∗ to satisfy the last equation. In this case, similar to
the Neyman–Pearson lemma, we propose to adopt a probabil-
ity distribution to assign the optimal treatment. Analogous to
the fact that the optimal test in Neyman–Pearson lemma is the
likelihood ratio test, our optimal treatment rule depends on the
benefit-risk ratio, δY (X )/δR(X ).
Remark 2. When there is no treatment heterogeneity on safety
outcomes in the population, Theorem 1 still applies with
δR(X ) = c, which is a special case of our general scenario allow-
ing δR(·) to depend on X .
4. Estimation of the Optimal Treatment Rules
In this section, we propose two learning algorithms to estimate
the optimal treatment rules using data collected from a random-
ized trial: regression-based learning and O-learning (abbrevi-
ated for outcome weighted learning) in the benefit-risk frame-
work. In the subsequent development, we assume that data con-
sist of (Yi,Ri,Ai,Xi) for i = 1, . . . , n.
4.1. Regression-Model-Based Learning Algorithm (BR-M
Learning)
Our first algorithm is based on explicitly estimating the solution
as given in Theorem 1. We use the empirical observations to fit
regression models for Y given (A,X ) and for R given (A,X ),
respectively. From the fitted model, we can estimate δY (X ) and
δR(X ) by δ̂Y (X ) and δ̂R(X ). LetM̂ = {x : δ̂Y (x)̂δR(x) ≤ 0} and
α̂∗ = τ − R̄1 − n
−1∑n
i=1[̂δR(Xi)I (̂δY (Xi) > 0,Xi ∈ M̂)]
n−1
∑n
i=1 I(Xi ∈ M̂c)
,
where R̄1 is the average risk outcome in subjects with A = 1.
Theorem 1 implies that the optimal treatment rule can be esti-
mated by D̂(X ) = sign( f̂ (X )), where
f̂ (X ) =
{
sign(̂δY (X )), X ∈ M̂
sign
(̂
δY (X )− λ̂δ̂R(X )
)
, X ∈ M̂c
with λ̂ = 0 if ∑n
i=1 δ̂
+
R (Xi)I(Xi ∈ M̂c)∑n
i=1 I(Xi ∈ M̂c)
≤ α∗,
and otherwise, λ̂ is the solution to∑n
i=1 δ̂R(Xi)I(Xi ∈ M̂c, δ̂R(Xi) > 0, δ̂Y (Xi)/̂δR(Xi) > λ)∑n
i=1 I(Xi ∈ M̂c)
+
∑n
i=1 δ̂R(Xi)I(Xi∈M̂c, δ̂R(Xi)<0, δ̂Y (Xi)/̂δR(Xi)<λ)∑n
i=1 I(Xi∈M̂c)
=α∗.
The regression models can be fitted by linear regression with a
sparse penalty when the number of covariates is large.
4.2. Outcome-Weighted Learning Algorithm (BR-O
Learning)
Our second algorithm directly solves the empirical version of
(3.2) using machine learning approaches. This approach is a
nontrivial extension of the nonconstrained O-learning where
maximizing benefit without risk control is the goal. Denote



















Ai f (Xi) ≥ 0
) ≤ τ. (4.1)
However, due to the discontinuity of the indicator function cor-
responding to the zero-one loss, solving the above constrained
optimization problem in (4.1) is anNP-hard problem (Natarajan
1995). Thus, instead of using the zero-one loss in the optimiza-
tion,we consider other types of surrogate loss functions andpro-
pose feasible algorithms to obtain solutions.
First, following Liu et al. (2014), we modify the above opti-
mization problem to (a) reduce the variability of weights (Yi/pi)
in the objective function, and (b) handle the situation that the
weights in the objective function can be negative, especially after
(a). Specifically, for (a), instead of using the original Y as out-
comes, we first regress Y on X and let the residuals be the out-













I(A = D(X ))
p(A|X ) {Y − m(X )}
]
,
wherem(X ) is any function of X . For (b), we note
E
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I(A · sign(Y ) = D(X ))
p(A|X ) |Y |
}
.
This suggests that the original optimization problem can be
modified as follows. DefineY ∗i = |Yi − m(Xi)|, A∗i = sign{Yi −












I(Ai f (Xi) ≥ 0) ≤ nτ. (4.2)
Since the indicator function in the objective function is dis-
continuous, we introduce a slack variable as the usual sup-
port vector machine, and adopt the kernel tricks to estimate
f . Specifically, we let f (X |β) = β0 +
∑n
j=1 β jK(X,Xj) where
K(·, ·) is a reproducing kernel and introduce slack variables,













I(Ai f (Xi) ≥ 0) ≤ nτ,






, ξi ≥ 0 ∀i.
(4.3)
Here, ‖ f ‖2H is the norm for the reproducing kernel Hilbert
space, which is equivalent to βT(0)Kβ(0) with K being the kernel
matrix and β(0) = {β1, . . . , βn}T .
In the above optimization, the nonconvex indicator func-
tion in the constraint makes computation difficult. To avoid
this discontinuity, we approximate I{A f (X ) ≥ 0} by the follow-
ing shifted ramp loss (Huang, Shi, and Suykens 2014, see also
Figure . Comparison of zero-one loss, hinge loss, and shiftedψ -loss∗∗ : Shiftedψ -
loss is defined asψ(η, x) = f1(η, x)− f0(η, x) = η−1(x + η)+ − η−1(x)+ .
Figure 1):
ψ(η, x) = f1(η, x)− f0(η, x) = η−1(x + η)+ − η−1(x)+.
As we can see that ψ(η, x) ≥ I(x ≥ 0), thus the shifted ψ-loss
serves as an upper bound of the zero-one loss function. There-
fore, if we can control the risk under loss function ψ(η, x), we
can also control the risk under the zero-one loss. In summary,













η−1{Ai f (Xi)+ η}+ − η−1{Ai f (Xi)}+
] ≤ nτ,






, ξi ≥ 0 ∀i.
(4.4)
We present the detailed algorithm for solving the above opti-
mization problem in the Appendix. Briefly speaking, by express-
ing the nonconvex loss function as the difference of two convex
functions, the DC algorithm (Tao and An 1998) can be applied
for optimization, and the tuning parameters are chosen by cross-
validation. To stabilize optimization, all covariates will be stan-
dardized before fitting the DC algorithm.
5. Simulation Studies
We simulated 10 iid covariates, X1, . . . ,X10, from a
Uniform(0, 1) distribution. The efficacy responsesY and safety
responses Rwere generated from two continuous distributions,
Y = 1 − 2X1 + X2 − X3 + hY (X,A)+ εY ,
R = 2 + X1 + hR(X,A)+ εR,
where εY follows N(0, 1), εR follows a truncated standard nor-
mal distribution (truncated at 1), hY (X,A) and hR(X,A) are the
interaction terms between covariates and treatment for the effi-
cacy and risk outcome, respectively. Here A takes two values: 1
(experimental therapy) and −1 (standard of care), and the ran-
domization probability is 0.5. In the first simulation setting, we
considered the decision rules for both risk and efficacy to be lin-
ear, that is,
hY (X,A) = 2(1 − X1 − X2)A, hR(X,A) = (1 + X1 − X2)A.
Figure . Regions of optimal treatment rules with τ = 1.75 in the first simulation
setting.
In this setting, regardless of whether all subjects are given the
experimental therapy or standard treatment, the average effi-
cacy values do not vary greatly and they are both close to
0. However, the risk of receiving the experimental therapy is
much higher (3.503) as compared to the standard treatment
(1.496). If ignoring the risk outcomes, the optimal treatment
strategy based on the efficacy alone results in a maximal effi-
cacy of 0.670 while the average risk reaches 2.495. Therefore, if
the safety outcome above some level, say 2.0, is of great con-
cern, this optimal treatment strategy is highly risky and not
acceptable.
To illustrate how the risk constraint may affect the optimal
treatment decision boundary, in Figure 2 we plot these bound-
aries and present the partition of optimal treatment regions.
Without the risk constraint, the optimal treatment decision
boundary is a linear function, X1 + X2 = 1, so the optimal
treatment for subjects in regions A and B is the experimental
therapy, TRT, because the benefit function δY (X ) is positive in
these regions. Similarly, the optimal treatment for subjects in
region C is the standard of care, SOC, because there is no gain in
terms of the efficacy for TRT. However, when considering risk
constraint, subjects in region B originally with TRT the as the
optimal treatment should be changed to receiving SOC instead,
since the benefit gain from TRT is moderate but the average
risk is higher for this group as demonstrated by the contour
lines of the risk differences. Subjects in region A maintain TRT
as their optimal treatment taking into account of risk because
the benefit is higher in this group. Likewise, subjects in region
C maintain SOC as the optimal treatment since SOC shows
a higher benefit and the risk is always lower than TRT. This
region mimics the real world scenario where a safer medication
is preferred when the efficacy is similar.
For each simulated data, we applied the proposed two meth-
ods to estimate the optimal treatment rules, where we varied the
risk threshold τ from 1.75 to 2.25. In the BR-M learning, we
estimated both δY (X ) and δR(X ) using linear regression models
with interactions between X andA included.We then estimated
the optimal treatment rule using the expression in Section 4.1,
where λ̂was calculated using a grid search algorithm. In the BR-
O learning, we chose the kernel function to be a linear kernel,
that is, K(x, x) = xTx. The DC algorithm was used to solve the
optimization problem, where at each iteration we used an exist-
ing quadratic programming package (“ipop” in R package kern-
lab https://cran.r-project.org/web/packages/kernlab/kernlab.pdf)
for the optimization. The tuning parameters, C and δ, for BR-
O were chosen by two-fold cross-validation. The data were split
into a training set and a testing set. On the training set, the
optimal treatment rule was computed with the risk constraint.
On the testing set, the empirical average of the efficacy out-
come under the derived rule was computed and used as the
criterion for the cross-validation. We let C vary from 0.5 to 2
and δ between 0.01 and 0.05. To compare different methods,
we independently generated a validation dataset of size 20,000
and applied the estimated decision rules to the validation data
to assess the predicted efficacy and risk on this large testing set.
We also calculated the efficacy of the theoretical optimal treat-
ment rule using Theorem 1.
The simulation results from 100 replicates for this setting are
shown in Table 1. BR-M and BR-O perform similarly: with a
more lenient threshold τ , the average risk increases and average
efficacy also increases. Both methods control the risk to be close
Table . Estimated average risk and optimal benefit in the first simulation setting† .
τ Efficacy n Method M-risk (sd) M-effic (sd) P-risk (dev) P-effic (dev) Accuracy
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-Q . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
NOTE: † : “Efficacy” is the theoretical efficacy value under the risk constraint; “M-risk” is the mean of the predicted risk in the validation data; “M-effic” is the mean
of the predicted efficacy using an independent validation dataset of size ,; “sd” is the empirical standard deviation; “P-risk” is the median of the predicted risk
in the validation data; “P-effic” is the median of the predicted efficacy using an independent validation dataset of size ,; “dev” is the median of the absolute value
of the deviation from the median; “Accuracy” is the proportion of subjects whose predicted optimal treatments agree with the true optimal treatments. The numbers in
the parentheses are the median absolute deviation from  replicates.
to the prespecified level and the estimated optimal treatment
agrees with the true optimal treatment for most subjects (pro-
portion of agreement greater than 85%). With a smaller sample
size, BR-M provides a slightly larger efficacy and a higher proba-
bility of identifying the correct optimal treatment.With increas-
ing sample size, bothmethods show improved performance. The
median efficacy and risk is similar to the mean. Since the true
optimal treatment boundary is linear, the model-free BR-Omay
not greatly improve the performance as compared to themodel-
based BR-M.
Next, we examined a procedure to rank variable importance
using the magnitude of the coefficients of the fitted linear opti-
mal treatment rule. In this simulation setting, the first two fea-
ture variables were equally informative (same coefficient on the
optimal treatment rule) and the other variables were noise. The
average estimated rank based on the absolute value of the fitted
coefficient is 1.46 (sd = 0.50) for X1 and 1.53 (sd = 0.50) for
X2, where the true rank for both variables is 1.5. The eight noise
variables have an average rank of 6.50 across 100 simulations,
while the true rank is also 6.5. These results suggest that using
the magnitude of the coefficients of the optimal rule to deter-
mine variable importance is effective when the true optimal rule
is linear.
In the second simulation setting, we considered a nonlinear
efficacy and safety boundaries by letting
Y = 1 − 2X1 + X2 − X3 + hY (X,A)+ εY ,
R = 2 + X1 + hR(X,A)+ εR,
where εY and εR were generated the same as in the previous set-
ting but
hY (X,A) = 8(1 − X21 − X22 )A, hR(X,A) = (X1 + X2 − 0.3)A.
The covariates and treatment assignments were the same as set-
ting 1. Figure 3 illustrates three regions partitioned by the non-
linear optimal treatment boundaries. The optimal treatment for
subjects in Region C is SOC due to a negative benefit function.
However, the risk of treating subjects in region B with TRT is
too high (δR(X ) > 0 with large magnitude). Thus, for region B,
the optimal treatment should be switched to SOC when consid-
ering risk regardless of a slightly inferior efficacy on SOC. This
scenario is similar to setting 1 except that the optimal decision
boundaries are nonlinear. The average risk is 2.661 and the the-
oretical maximal efficacy without risk constraint is 3.602.
Figure . Regions of optimal treatment ruleswith τ = 2.0 in the second simulation
setting.
The results from setting 2 are summarized in Table 2. Both
methods adequately control the risk since the risk outcome is
simulated from a linear model. For small sample size, BR-M has
slightly higher efficacy and a smaller variability in estimating
benefit function since it is model-based. The variability of BR-
O is larger than BR-M, leading to some outliers and a slightly
smaller mean benefit. When considering median benefit, BR-O
performs as well as BR-M even for small sample size: for τ = 2.0
and n = 200, the median efficacy for BR-O and BR-M are: 1.801
and 1.834, respectively.With larger sample size, the variability of
BR-O is reduced and it has a greater mean benefit (and a greater
median benefit) than BR-M under all values of τ .
In the above two simulation settings, we also estimated the
optimal rules using the BR-O under a Gaussian kernel. For
the Gaussian kernel, following Jaakkola, Diekhans, and Haus-
sler (1999); Wu, Zhang, and Liu (2010), we used a heuris-
tic method to choose the spread parameter σ as σ = 1/d2m,
where dm was themedian pairwise Euclidean distance defined as
median{‖Xi − Xj‖ : Ai = Aj}. The performance was very simi-
lar to using the linear kernel with a slightly larger efficacy in the
nonlinear setting. However, the computational time using the
Gaussian kernel was much more intensive. Therefore, a linear
kernel for BR-O may be sufficient in practice.
As a comparison, we also implemented a utility-based
method inspired by Thall, Nguyen, and Estey (2008). Let
Table . Estimated average risk and optimal benefit in the second simulation setting† .
τ Efficacy n Method M-risk (sd) M-effic (sd) P-risk (dev) P-effic (dev) Accuracy
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
. .  BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
 BR-M . (.) . (.) . (.) . (.) % (.%)
BR-O . (.) . (.) . (.) . (.) % (.%)
NOTE: † : See Table .
U (Yi,Ri) = Yi − βRi denote a utility function, where β reflects
the equivalent benefit loss for one unit increase in risk and is
computed as the regression coefficient ofYi on Ri using the pop-
ulation data. Specifically, β = 0.091 and 0.093 for the two simu-
lation settings, respectively. Following Thall, Nguyen, and Estey
(2008), we fitted a bivariate copula model to estimate the joint
distribution of efficacy and risk outcome including treatment by
covariate interactions, and computed the expected utility given
the joint distribution for each patient. The optimal treatment
was estimated as the one leading to a higher utility value. Under
simulation setting 1, the mean efficacy (sd) was 0.622 (0.015)
and 0.634 (0.008) for n = 200 and n = 400, respectively. The
mean risk (median absolute deviation) was 2.620 (0.078) and
2.629 (0.053), respectively. The median efficacy and risk were
similar to the mean. For setting 2, the mean (sd) of the efficacy
was 3.521 (0.017) and 3.526 (0.012), for the two sample sizes,
respectively. The corresponding mean (sd) for the risk outcome
was 2.563 (0.023) and 2.558 (0.017), respectively. These results
show that the utility-basedmethod captures the optimal efficacy,
but does not provide control over the risk at a particular level.
Thus, the higher efficacy is achieved by allowing a higher risk,
where the latter may potentially be over the tolerance bound.
Next, we explored a modified utility-based method that pro-
vides more control over individual risk outcome by imposing a
safety admission rule: for each individual, we examine whether
the previously estimated utility-based treatment rule will lead
to a risk outcome (or estimated risk outcome) exceeding the
threshold τ ; if so, we select the safer treatment with a lower risk
regardless of the efficacy. The results under the first simulation
setting show that utility-based approach with safely admission
rule leads to the risk outcome being controlled well below the
threshold, at the price of a lower efficacy than BR-M and BR-
O. For example, for setting 1, the mean efficacy across simula-
tions was 0.016 and the mean risk was 1.49 when τ = 2.0 and
n = 200. When τ = 2.25, the mean risk and efficacy was 1.50
and 0.0164, respectively. The efficacy is close to that of the non-
personalized, “one-size-fits-all” rule (treatment effect of 0.003).
Thismay be due to that the risk constraint is imposed at the indi-
vidual level for this utility-based approach, while for BR-M and
BR-O the risk is controlled on average (across patients). Thus,
when strictly enforcing each individual’s risk to be below τ is
desirable, utility-based method with a safety admission rule is
preferable.
6. Application to DURABLE Trial
We applied our method to DURABLE study (Fahrbach et al.
2008) introduced in Section 2. A more detailed description
of the study design was previously published (Fahrbach et al.
2008; Buse et al. 2009). A major objective of treating diabetes
patients was to lower patients’ blood glucose measured by A1C.
Similar to the original report in Fahrbach et al. (2008), our
efficacy endpoint (the benefit) was A1C change from baseline
at 24 weeks (last observation carried forward [LOCF] to 24
weeks). Our safety (the risk) endpoint was measured by daily
hypoglycemic event rate. We considered 18 relevant covariates
measured at the baseline, including baseline A1C, fasting blood
glucose, fasting insulin, adiponectin, blood pressure, 7 points
self-monitored blood glucose, duration of diabetes, weight,
height, blood pressure, body mass index (BMI). The covariates
were standardized before fitting the model and the tuning
parameters for BR-O were chosen by two-fold cross-validation
similar to the simulation studies.
We included randomized patients who received at least one
treatment, which consisted of 965 patients on lispro mix and
980 patients on insulin glargine. Within a reasonable range, we
examined different threshold values for daily hypoglycemic rates
(τ = 0.063, 0.064, 0.065, 0.066, 0.067) as our safety constraint.
To compare the performance of different methods and eval-
uate the importance of the variables in this analysis, we ran-
domly split the full data into a training set and a testing set, so
the performance can be assessed using the testing set. Among
1945 patients, we randomly selected 300 patients as a training
set, and used the rest 1645 patients as a testing set. We applied
the proposed algorithms (BR-M, BR-O) to the training set, and
obtained the average efficacy and safety outcomes under the esti-
mated optimal treatment assignments on the testing set. Fur-
thermore, to minimize influence on the variability due to select-
ing training and testing set by chance, we repeated this proce-
dure 100 times.
We show in Table 3 the average benefit and risk obtained
by BR-M and BR-O under risk constraints, and compare with
results obtained by O-learning without controlling for the risk
(Zhao et al. 2012). We see that the average risks are reasonably
controlled for both BR-M and BR-O at all constraint value of τ .
BR-O produces a more conservative result in terms of a lower
rate of hypoglycemia on the testing set as compared to BR-M,
and thus a slightly lower average benefit. The average benefit
Table . DURABLE study analysis results.
Risk(τ ) Method Risk-training Risk-testing Benefit-training Benefit-testing
. BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
. BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
. BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
. BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
. BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
∞ BR-M .(.) .(.) .(.) .(.)
BR-O .(.) .(.) .(.) .(.)
NOTE: We randomly selected  patients as a training dataset, used the rest  patients as a testing dataset, and repeated this  times. The average benefit, risk, and
their standard deviations are shown.
Table . DURABLE study analyses results: ranking of baseline biomarkers based on average standardized effects over  repetitions.
τ = . . . . . ∞
Baseline AC      
BMI      
Fasting blood glucose      
Height      
Adiponectin      
Duration of diabetes      
Body weight      
Diastolic blood pressure      
Fasting insulin      
Heart rate      
Systolic blood pressure      
Glucose: Morning before meal      
Glucose:  am at night      
Glucose: Evening before meal      
Glucose: Morning  hr after meal      
Glucose: Evening after meal      
Glucose: Noon before meal      
Glucose: Noon  hr after meal      
increases as a function of threshold τ , indicating that allowing
a more lenient risk control leads to gain in efficacy. The max-
imal benefit for the optimal treatment rules under O-learning
without constraint (τ = ∞) is the highest (1.738).
Since a linear kernel was used for the BR-O algorithm, the
treatment decision boundary can be expressed as a linear com-
bination of the covariates. The standardized effects can be used
to compare influences of the covariates on the decision bound-
ary and rank the importance of covariates (absolute value of the
standardized coefficient). The ranking based on covariates’ aver-
age effects from 100 random splits indicates that the top three
most important variables are, in turn, baseline fasting blood glu-
cose, BMI, and A1C (see Table 4). The variables with highest
importance are not sensitive to the threshold of the risk con-
straint. The less important variables can change order in the
presence and absence of risk constraint (e.g., fasting insulin and
heart rate).
To determine an appropriate risk bound for the final model,
we control the rate of hypoglycemic event to be below the
observed incidence rate in the low risk treatment arm (insulin
glargine) in DURABLE trial, an incidence rate of 0.5 per week
for each patient (Buse et al. 2009, Table 2, a total of 530 inci-
dences per week for 1046 patients), which corresponds to two
hypoglycemic events per month (i.e., τ = 0.065). To further
illustrate an empirical method to choose the threshold, we adapt
the net clinical benefit (NCB), which was proposed to weigh
benefits against harms of a treatment based on the difference
between expected benefit and expected harm (Sutton et al. 2005;
Lynd 2006). Specifically, the NCB at each threshold was com-
puted as Y − 1.5R, where Y was the average efficacy obtained
on the testing set using BR-O, and R was the corresponding
average risk on the testing set (Table 3). The scaled association
coefficient of 1.5 was obtained from the full data, similar to the
method used for constructing the utility function. The increase
in NCB with increasing threshold was 0.0026, 0.0029, −0.0024,
and 0.0098 for τ changing from0.063 to 0.067 at an increment of
τ = 0.001. Thus, when τ = 0.065 the change in NCB is neg-
ative for the first time, that is, the change in benefit does not
outweigh the change in risk. This analysis further supports the
choice of τ = 0.065 as the threshold.
Next, we present the estimated optimal treatment rule
obtained by BR-O and O-learning using all 1945 patients with
τ = 0.065. To visualize the influence of top ranking variables
on the personalized treatment rules, in Figure 4, we plot the
decision boundary as a function of two covariates with A1C
values fixed at prespecified levels and all other covariates fixed
Figure . Estimated optimal treatment decision boundaries (based on all subjects) stratified by baseline AC† . † : Except BMI, fasting blood glucose, and AC, all other
covariates are fixed at samplemean level. Red solid line: BR-O (τ = 0.065). Black dashed line: O-learningwithout risk constraint. Patients above the lines are recommended
to take mix / and patients below the lines are recommended to take insulin glargine.
at sample means. The proportion of patients recommended to
take mix 75/25 based on BR-O (40%, 33%, 23%) is decreas-
ing with increasing A1C (7.8%, 8.8%, 10.3%). Similar trend was
also found for O-learning (62%, 55%, 44%). From Figure 4, we
observe that for patients with a higher BMI, mix 75/25 is rec-
ommended. This finding is consistent with clinical knowledge
on the mechanism of these two treatments: because patients
with a higher BMI often have more food intake, a treatment
that can more efficiently lower the post prandial blood glucose,
namely, mix 75/25, is more desirable. Comparing the change
of slopes for the decision boundary with and without risk con-
straint, Figure 4 indicates that when considering hypoglycemic
events, fasting blood glucose plays a more important role. In
addition, the two decision boundaries become more divergent
when the fasting blood glucose is low. This observation reflects
the fact that patientswith a lowblood glucose level are at a higher
risk of experiencing hypoglycemia events, which is consistent
with the diabetes treatment guidance (American Diabetes Asso-
ciation and others 2014).
Finally, when comparing with the utility-based method, the
utility function was computed as U (Y,R) = Y − βR, where
β = 0.0041 is the regression coefficient ofY on R using the full
data. Thus, on average one unit increase in the risk is reflected
as 0.0041 unit decrease in the benefit. Following Thall, Nguyen,
and Estey (2008), we first estimated the joint distribution of Y
and R using a copula model including treatment and covariate
interactions. Using this joint distribution, we then calculated the
expected utility function and maximized it to find the optimal
treatment rule. The estimated optimal treatment rule achieves
an average efficacy of 1.742 (sd = 0.049), similar to O-learning
without the risk constraint. However, similar to that observed in
the simulation studies, the average risk is also higher (0.0704, sd
= 0.003) than BR-M or BR-O. Therefore, the utility function-




In this work, we introduce a risk constraint to the estimation of
optimal personalized treatment rule, so that the identified rule
not only maximizes efficacy but also controls the average risk to
be below a prespecified threshold. We have proposed twometh-
ods to the constrained optimization, of which BR-M relies on
valid models for both efficacy and safety outcomes while BR-O
directly maximizes an approximation to the objective function
without modeling. In our simulation and data analysis, we used
linear models in BR-M, so if the linear model is misspecified,
BR-M may not always control the risk in a testing dataset. In
contrast, as seen from our numerical studies, BR-O controls the
risk at the prespecified level on both the training and testing
data, and maintains robustness against the model misspecifica-
tion of δR(X ). From a computational perspective, BR-M only
requires fitting two regression models and solving a single-
parameter monotone optimization problem, which is fast. For
BR-O, the computation can be improved by using reasonable
initial values, for example, those estimated under the hinge loss.
In our approaches, the choice of threshold value for con-
trolling the risk is important. Ideally, the threshold should be a
clinicallymeaningful safety/risk bound specified by clinicians or
policy makers. When such a clinically meaningful bound is not
available, our method provides a complete picture of the trade-
off between benefit and risk for a range of threshold values. In
our application example, several thresholds were examined, and
the final bound was controlled at the average level observed in
the low risk arm. Furthermore, we illustrate using the change
in NCB (Sutton et al. 2005; Lynd 2006) as an empirical guide to
determine the threshold. A limitation of these proposals to find
the threshold is that they do not take into account the variability
rising from estimating the optimal rule. A better alternative
is to use bootstrap resampling to examine the probabilistic
behavior of the risk outcome (e.g., whether the mean or median
risk across bootstrap samples is below the threshold bound).
A Bayesian approach may also be suitable. When two optimal
treatment rules have similar efficacy but different safety, which
are both under the bound, we propose to select the treatment
strategy that achieves the smallest threshold.
Alternative Bayesian approaches to handlemultivariate bene-
fit and risk outcomes include defining ameaningful utility func-
tion as exemplified in Houede et al. (2010), Thall, Nguyen, and
Estey (2008), and Thall (2012), although the definition of a util-
ity function may be difficult in cases without a consensus. As
demonstrated in the simulation study and application to our
motivating example, using utility function may yield a higher
benefit but at a price of an increased risk potentially higher than
the threshold. A solution is to impose amore strict safety admis-
sion rule at the individual level as in Section 5. However, as
observed in the simulations, it may result in a conservative treat-
ment rule with a low risk but at the price of a lower efficacy.
There is a link between the utility-based approaches and BR-
O: by redefining the value function as negative infinity when the
average risk is greater than the bound, the risk constraint can be
directly enforced into the value function.However, the redefined
value function will be nonsmooth with a singleton component.
Thus, computation may be more difficult and potentially caus-
ing numeric instability.
7.2. Extension toMultiple Risk Constraints
Patients’ perspective on acceptable risk threshold may depend
on the goal of the treatment they are receiving (e.g., disease pre-
vention, chronic treatment), their genetic risk factors, or their
perception of susceptibility of a disease. Thus, it is desirable
to include multiple thresholds or risk constraints in estimating
the optimal treatment depending on patient-specific features or
preferences. Extensions to handle multiple constraints can be
incorporated in BR-O learning framework, although it requires
determination of thresholds for multiple risk outcomes.
Consider K types of risk outcomes, denoted by
R(1), . . . ,R(K), each with a threshold value τ (1), . . . , τ (K),
















≤ τk, k = 1, . . . ,K.
Following the same derivation as in Theorem 1, by introduc-
ing K Lagrange-multipliers, we can show that the optimal deci-
sion rule takes a similar form as described in Theorem 1 with λ∗
replaced by outcome-specific λ∗k . BR-O as given in (4.4) can also
be extended to include multiple constraints in the optimization.
Finally, we also note that the same procedure is applicable to
control group-specific risks, in which different risk bounds may
be imposed on difference subgroups of patients. For example,
patients who are more susceptible to adverse events may require
tighter control on their risk outcomes. In this case, the above
procedure is applicable when each constraint is conditioned on
the corresponding subgroup.
7.3. Extension toMultiple Treatments
The same idea in this article can be extended to the applications
with multiple treatment arms. Assume that A has m treatment
levels so that the decision functionD(X )mapsX to one of these







E[Y |A = j,X]I(D(X ) = j)} ,





E[R|A = j,X]I(D(X ) = j)} ≤ τ.
Hence, BR-M can be extended by solving an empirical version
of a constrained equation. To extend BR-O, we can replace the
objective function in the optimization by a consistent continu-
ous loss for multicategory learning (Lee, Lin, and Wahba 2004;
Liu and Yuan 2011), where D(X ) is replaced by a vector of
decision functions ( f1, . . . , fm) with each component corre-
sponding to each level of A, and the indicator function in the
constraint, which is equivalent to (I(A = j) f j(X ) ≥ 0), can be
approximated by the shiftedψ-loss. A computational algorithm
similar to BR-O can be carried out but will be more involved.
Further investigation is warranted for implementation.
Appendix A: Proof of Theorem 1
If E[δR(X )+|X ∈ Mc] ≤ α∗, then every f (x) satisfies the con-
straint so the optimal f ∗(X ) = sign(δY (X )). Thus, for the fol-
lowing discussion, we assume E[δR(X )+|X ∈ Mc] > α∗. Sup-
pose f ∗(x) to be the optimal solution in this region. We claim
E[δR(X )I( f ∗(X ) > 0)|X ∈ Mc] = α∗. To see this, we note that
f ∗(X ) cannot have the same sign as δR(X ) because other-
wise, E[δR(X )I( f (X ) > 0)|X ∈ Mc] = E[δ+R (X )|X ∈ Mc] > α∗.
Thus, ifE[δR(X )I( f ∗(X ) > 0)|X ∈ Mc] < α∗, thenwe can change
sign of f ∗(X ) in a small region of X where f ∗(X ) and δR(X ) have
the opposite signs so that E[δR(X )I( f ∗(X ) > 0)] is closer to α∗.
However, since δY (X )δR(X ) > 0, this change will only increase the





δY (X )I( f (X ) > 0)|X ∈ Mc
}
subject to E[δR(X )I( f (X ) > 0)|X ∈ Mc] = α∗.
After introducing the Lagrange multiplier, f ∗(x)maximize,
E
[{δY (X )− λδR(X )} I( f (X ) > 0)|X ∈ Mc]
subject to E[δR(X )I( f (X ) > 0)|X ∈ Mc] = α∗. Clearly,
I{ f ∗(X ) > 0} = I [{δY (X )− λδR(X )} > 0] ,
where λ solves equation,
E
[
δR(X )I ({δY (X )− λδR(X )} > 0) |X ∈ Mc
] = α∗.
The last equation is equivalent to,
E
[
δR(X )I{δR(X ) > 0, δY (X )/δR(X ) > λ}|X ∈ Mc
]
+E [δR(X )I{δR(X ) < 0, δY (X )/δR(X ) < λ}|X ∈ Mc] = α∗.
The left-hand side of the equation is strictly decreasing in λ which
is equal to E[δR(X )+] if λ = 0 and E[δR(X )I{δR(X ) < 0}|X ∈
Mc] ≤ α∗ if λ = ∞. Thus, this equation has a unique solution
denoted by λ∗. Consequently, the optimal treatment regime f ∗(X )
has the same sign as sign(δY (X )− λ∗δR(X )).
Interestingly, when X ∈ M where δY (X ) and δR(X ) take oppo-
site signs, we note that the sign of δY (X ) is the same as the sign of
δY (X )− λ∗δR(X ). So we have the results of Theorem 1.
Appendix B: Detailed Algorithm for BR-O-Learning
Here, we describe the detailed computational algorithm for solving
(4.4). At each iteration of the DC algorithm, after introducing addi-


















ζi − v̂i(β, β(l))
} ≤ δnτ,




j=1 β jK(Xi,Xj )
}
, ξi ≥ 0




j=1 β jK(Xi,Xj )
}
, ζi ≥ 0, ∀i,
where v̂i(β, β(l)) = {Ai f (Xi|β)}I(l)i and I(l)i = I{Ai f (Xi|β(l)) >
0}. Note that the presence of ξi in the objective function guarantees






However, since we only weigh the summation of ζi by a small
weight C/n. The objective in the above optimization is approxi-
mately equivalent to (4.4).








































Taking the derivativewith respect to ξi, ζi, β0, andβ(0), and set them






















βi − π Ripi AiI
(l)
i − αiA∗i + κiAi = 0, ∀i = 1, . . . , n.
Let θ = (π R1p1 A1I
(l)
1 + α1A∗1 − κ1A1, . . . , π Rnpn AnI
(l)
n + αnA∗n −









)T , Rp = (R1/p1, . . . ,Rn/pn)T , A =
(A1, . . . ,An)T , A∗ = (A∗1, . . . ,A∗n)T , and RIpA =
(R1/p1A1I(l)1 , . . . ,Rn/pnAnI
(l)
n )
T . By substituting the equations











κ − πRp 
 n−1C1, 0 ≤ π, 0 
 κ,
π1TRIpA + αTA∗ − ATκ = 0,
where 
 is the by element inequality. Let ω = (π,αT , κT )T , 1δ =
{−δnτ, 1T , δ1}T , H = {RIpA, diag(A∗), diag(−A)} which is a n ×
(2n + 1)matrix,
W =




























In particular, package ipop can be used to obtain the solution.
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